Flat-panel detector-based volume computed tomography: A novel 3D Imaging technique to monitor osteolytic bone lesions in a mouse tumor metastasis model
Flat-panel detector-based volume computed tomography: A novel 3D Imaging technique to monitor osteolytic bone lesions in a mouse tumor metastasis model
复制标题
DOI：
10.1593/neo.07466
复制
发表时间：
2007-09-01
期刊：
影响因子：
4.8
通讯作者：
Alves, Frauke
中科院分区：
文献类型：
--
作者：
Missbach-Guentner, Jeannine;Dullin, Christian;Alves, Frauke
骨转移是乳腺癌患者死亡的重要原因。因此，动物模型与各种成像技术相结合，对新疗法的临床前评估有很高的需求。我们评估了平板体积计算机断层扫描 (fpVCT) 对无创检测严重免疫缺陷小鼠心内注射 MDA-MB-231 乳腺癌细胞后发生的溶骨性骨转移的适用性。采用 200 μm 各向同性分辨率的单次 fpVCT 扫描来检测整个骨骼内的骨质溶解。通过 fpVCT 识别的溶骨性病变与 Faxitron X 射线分析相关，随后通过组织病理学检查得到证实。通过 fpVCT 获得的各向同性三维图像数据集是皮质骨内病变范围精确可视化和骨丢失测量的基础。此外，fpVCT 成像可以连续监测每个转移部位的生长动力学，并可视化更复杂的骨骼区域（例如头骨）的病变。我们的研究结果表明，fpVCT 是一种强大的工具，可用于监测体内溶骨性病变的发生和进展，并可进一步开发以监测疾病过程中抗转移治疗的反应。
Skeletal metastasis is an important cause of mortality in patients with breast cancer. Hence, animal models, in combination with various imaging techniques, are in high demand for preclinical assessment of novel therapies. We evaluated the applicability of flat-panel volume computed tomography ( fpVCT) to noninvasive detection of osteolytic bone metastases that develop in severe immunodeficient mice after intracardial injection of MDA-MB-231 breast cancer cells. A single fpVCT scan at 200-mu m isotropic resolution was employed to detect osteolysis within the entire skeleton. Osteolytic lesions identified by fpVCT correlated with Faxitron X-ray analysis and were subsequently confirmed by histopathological examination. Isotropic three-dimensional image data sets obtained by fpVCT were the basis for the precise visualization of the extent of the lesion within the cortical bone and for the measurement of bone loss. Furthermore, fpVCT imaging allows continuous monitoring of growth kinetics for each metastatic site and visualization of lesions in more complex regions of the skeleton, such as the skull. Our findings suggest that fpVCT is a powerful tool that can be used to monitor the occurrence and progression of osteolytic lesions in vivo and can be further developed to monitor responses to antimetastatic therapies over the course of the disease.